| Dr Kate D Zimmerman, DO | |
|
22 Bramhall St, Portland, ME 04102-3134 | |
| (207) 662-7046 | |
| (207) 662-7025 |
| Full Name | Dr Kate D Zimmerman |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215030028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 1911 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
News Archive
Representative Paul Ryan is rebutting critics of his plan to turn Medicare into a "premium support" program, pointing to two existing programs that he says prove his approach would be better for beneficiaries. Don't believe it. The two programs he cites as prototypes — the insurance program for members of Congress and the Medicare prescription drug program — differ in critical respects from his proposal to sharply limit federal spending. The losers will be the beneficiaries who have to pay more.
Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.
A tiny molecule might help protect the pancreas from deadly disease and cancer. Tackling a mysterious process: There is a feeling that neglected cancers need more research and Pancreatic cancer is one of the least studied. Today, the survival rate is 3% for five years. Professor Petersen, at the School of Biosciences at Cardiff University, hopes his team's research can change that.
Results from a University of Pittsburgh study demonstrate that intensity-modulated radiation therapy (IMRT) for head and neck cancer can be uniformly delivered in a large health care system of academic and community cancer centers through a centralized planning and treatment process.
› Verified 1 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Representative Paul Ryan is rebutting critics of his plan to turn Medicare into a "premium support" program, pointing to two existing programs that he says prove his approach would be better for beneficiaries. Don't believe it. The two programs he cites as prototypes — the insurance program for members of Congress and the Medicare prescription drug program — differ in critical respects from his proposal to sharply limit federal spending. The losers will be the beneficiaries who have to pay more.
Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.
A tiny molecule might help protect the pancreas from deadly disease and cancer. Tackling a mysterious process: There is a feeling that neglected cancers need more research and Pancreatic cancer is one of the least studied. Today, the survival rate is 3% for five years. Professor Petersen, at the School of Biosciences at Cardiff University, hopes his team's research can change that.
Results from a University of Pittsburgh study demonstrate that intensity-modulated radiation therapy (IMRT) for head and neck cancer can be uniformly delivered in a large health care system of academic and community cancer centers through a centralized planning and treatment process.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kate D Zimmerman, DO 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-7046 | Dr Kate D Zimmerman, DO 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-7046 |
News Archive
Representative Paul Ryan is rebutting critics of his plan to turn Medicare into a "premium support" program, pointing to two existing programs that he says prove his approach would be better for beneficiaries. Don't believe it. The two programs he cites as prototypes — the insurance program for members of Congress and the Medicare prescription drug program — differ in critical respects from his proposal to sharply limit federal spending. The losers will be the beneficiaries who have to pay more.
Otsuka Pharmaceutical Co., Ltd. today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Samsca (generic name: tolvaptan) has been approved in Japan in 7.5-mg and 15-mg tablet forms for extended use for the additional indication of ADPKD. Also, the new dosage form of 30-mg Samsca tablets has received approval for the indication of ADPKD.
A tiny molecule might help protect the pancreas from deadly disease and cancer. Tackling a mysterious process: There is a feeling that neglected cancers need more research and Pancreatic cancer is one of the least studied. Today, the survival rate is 3% for five years. Professor Petersen, at the School of Biosciences at Cardiff University, hopes his team's research can change that.
Results from a University of Pittsburgh study demonstrate that intensity-modulated radiation therapy (IMRT) for head and neck cancer can be uniformly delivered in a large health care system of academic and community cancer centers through a centralized planning and treatment process.
› Verified 1 days ago
Thomas M Eslinger, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7010 Fax: 207-662-7025 | |
Dr. Christopher T Bowe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7010 Fax: 207-662-7025 | |
Sandra L Stevens, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 | |
Dr. Gregory Scott Heaphy, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Dr. Eric G Lowe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-7060 Fax: 207-662-7066 | |
Caitlin Bonney, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-3281 | |
Christopher James Watson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2381 |